Even companies that have obtained the necessary regulatory authorizations can encounter problems that ultimately prevent them from achieving commercial success. Several drugmakers have already won an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for their COVID-19 vaccines, with two also picking up full FDA approvals. Some hope to receive authorization or approval in the not-too-distant future. Get this delivered to your inbox, and more info about our products and services.

The company was the first to launch an investigational COVID-19 vaccine in a human trial. And, more importantly, Moderna recently requested an EUA in the U.S. and conditional approval in Europe. The U.S. Food and Drug Administration (FDA) set a Dec. 17 meeting with its Vaccines and Related Biological Products Advisory Committee to discuss Moderna’s trial data. Social distancing and the increase in people working from home driven by the spread of the coronavirus only serve to increase usage of AWS cloud services. Stock market history shows when the Nasdaq, S&P 500 and the Dow Jones Industrial Average fall into a downtrend, they take three out of four stocks down with it.

Vaxart (VXRT 0.53%) recently completed enrollment in the phase 1 trial of its investigational coronavirus vaccine. But something about Vaxart’s program makes it stand out from the crowd. The stock has a strong 95 out of a best-possible 99 EPS Rating and a superb A SMR Rating, according to IBD Stock Checkup. The EPS Rating tracks a company’s earnings strength, while the SMR Rating analyzes a company’s sales, margins and return on equity.

Of course, the ETF features plenty of holdings under its belt and Fincantieri is but one name among several. This is an underhanded way of saying you should monitor the equity unit’s performance where it’s traded in the Borsa Italiana, the nation’s stock exchange. When Vaxart began its phase 1 trial in October, it said it expected initial data in « the next few weeks, » so investors are hoping that the company may share some results in December. Pfizer (PFE 3.37%) and partner BioNTech (BNTX 6.48%) lead the coronavirus vaccine race based on their timeline.

  • Pfizer’s size makes it difficult for any single product to substantially change its stock price.
  • Moderna also has 15 other candidates in clinical trials and plans to heavily invest in expanding its pipeline.
  • As mentioned, as long as the stock market remains in a correction, it’s difficult for any stock to buck the downturn and climb higher.

That would be a large sum to add to its current revenues of $9.24 billion. But management hasn’t publicly committed to any pricing scheme yet, so the actual figures could wind up dramatically different. This year, Regeneron made headlines when doctors gave the company’s experimental antibody cocktail to President Trump after he contracted COVID-19. Though the cocktail is not authorized for use in people on oxygen or those who have been hospitalized for coronavirus, the hope is that it could prevent hospitalizations in the first place. It plans to manufacture up to 1 billion doses of mRNA-1273 during 2021, and based on its already-negotiated purchasing agreements, will likely sell them at prices of between $32 and $37 apiece. In the best-case scenarios, then, it could report between $32 billion and $37 billion in revenue.

Vaccine growth stocks

With a strong earnings stability rating of 5 (the lower the number, the more stable the earnings), VEEV stock has now earned a spot on the watchlist for IBD Long-Term Leaders. Zoom Video Communications’ videoconferencing and other tools are allowing many people who generally work in offices and other settings to more efficiently work from their homes during the pandemic. Moreover, its offerings are enabling people to hold virtual social events ranging from parties to funerals. If companies believe that Zoom’s products are increasing the efficiency of their workforces and their bottom lines, they’ll continue to use them after the pandemic is over. While the week ahead could include some coordinated actions by central banks to soothe anxiety, there are also likely to be more earnings warnings from multinationals across sectors. On the economic calendar, PMI prints from across the world will be watched closely, as well as reports on durable goods orders and the February employment report.

On a year-to-date basis, LUV is almost down 2% below breakeven, which is frustrating. Yes, on one hand, this performance compares favorably to many other airliners. is deriv com a brokerage firm we can trust However, the concept of retail revenge isn’t just about buying stuff. Rather, it signals that people miss the social experiences that make us human.

  • Amid all the market turmoil, energy sector eyes will be focused on Vienna as ministers gather to assess the economic situation and make a decision on output.
  • For instance, the new strain appears to be highly transmissible, imposing a massive problem for travel-related stocks to watch.
  • In an encouraging sign of resilience, the stock’s relative strength line remains right around new-high ground.
  • The FDA scheduled an advisory committee meeting to discuss the vaccine candidate on Dec. 10; this means a decision on the Pfizer-BioNTech vaccine may come sooner than a decision on Moderna’s.
  • However, that isn’t the case in some other parts of the world, and the emergence of new coronavirus variants could fuel demand for vaccines for a long time to come.

Quest on Thursday reported Q3 adjusted EPS of $4.31, up 145% year over year, on a 42.5% jump in revenue to $2.79 billion. Analysts polled by FactSet were looking for $3.72 a share on $2.72 billion in sales. Because Southwest specializes in discount fare, it’s admittedly disappointing that shares aren’t in the black for the year. Now, the equity unit faces the same technical threat that other airliners do, if not more so. Basically, LUV has been inside a downtrend since June of this year and omicron threatens to do more damage unless positive momentum takes over quickly. In the professional realm, it’s quite possible that the airline industry has been hurt the most from the pandemic.

Is Rivian Stock A Buy Or A Sell With Tesla Bull Expecting The Cybertruck To Be Out By Halloween?

A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Podcasts, Stitcher and Spotify (click the highlighted links). On the flipside, if omicron realizes the worst fears of infectious disease experts, then we might need to brace ourselves for a crash landing. As you know, Boeing is one of those companies that carried baggage heading into the Covid-19 crisis; namely, the software defects in the 737 Max 8 jetliner.

A later player to the vaccine race, Novavax hasn’t had the same success in the U.S. as Pfizer or Moderna. No pharmaceutical company has received as much positive press for its vaccine innovations as Pfizer. Earlier this month, CEO Albert Bourla was recommended by one InvestorPlace contributor for CEO of the year. Moderna was one of the first companies to have its executive team discuss address the omicron variant.

Moderna

Add the pandemic to the mix and you have a truly combustible situation. What’s worrisome for all involved is that over 3,200 people are onboard the affected ship, according to Louisiana Department of Health officials. Per News 18, anyone who tests positive during the disembarking process will either go directly home or self-isolate, with accommodations provided by the cruise ship operator. With the unfortunate development of the omicron variant, Carnival fundamentally appears to be back at square one. Quidel stock surged 26% to all-time highs Tuesday after receiving the FDA authorization. Currently, there is no proper buy point, as the stock rebounds above its 50-day line.

Vaccine Stocks to Watch as New Covid-19 Variant Strikes the Market

With the limited data that we have, we’re yet to see serious diseases or death stemming from the strain. Therefore, it’s important not to panic, but rather to assess travel-related stocks to watch with thoughtful vigilance. This is a big month for coronavirus stocks — in particular, vaccine stocks. That’s because two of the leaders in the coronavirus vaccine race have requested Emergency Use Authorizations (EUA). And many others are advancing in phase 3 trials or expecting key data from earlier trials.

How 10-year Treasurys could produce 20% returns, according to UBS

Another tiny company, Synairgen Plc of the U.K., was one of the last year’s investor favorites, soaring 2,520% on optimism for its inhaled treatment for Covid-19. Among the bigger companies still working on antivirals are Pfizer, Shionogi & Co. and Roche Holding AG with partner Atea Pharmaceuticals Inc. All plan to publish results from late-stage clinical trials by the end of the year. Shionogi’s pill could be a $2 billion drug, the Japanese company said Friday. The first pill to treat Covid-19 is on its way and vaccine producers are rolling out booster shots in wealthy countries. For investors, the next stage of the pandemic means a tougher landscape for stockpicking.

Most importantly, this issue isn’t just about health risks, but anticipation of such. Frankly, it doesn’t matter what you or I think about the omicron variant. If the market as a whole perceives serious threats, then we must respect that viewpoint because it’s the one that most influences price. As we enter the winter season, experts are warning that we should prepare for a long and cold one. That’s not exactly the most helpful condition for a pandemic, especially with the devastation we saw from the cold snap in February. One of the few positives of this latest twist in the crisis is that demand for vaccines increased, which may mitigate damage to some stocks to watch.

J&J is so big that its success doesn’t depend on any one product. The company’s diversified operations across healthcare and its status as a Dividend King position Johnson & Johnson stock as one of the safest stock picks for long-term investors. The company is selling its COVID-19 vaccine at cost during the pandemic, meaning that it doesn’t affect the company’s profitability for now. Far affiliate pro fewer doses of J&J’s vaccine have been administered so far compared to the Pfizer-BioNTech and Moderna vaccines. This gap is due to several factors, including a lower overall efficacy for J&J’s vaccine and some rare blood-clotting issues. The German biotech innovator told Business Insider that it is already at work on the development of an adapted vaccine to combat the omicron variant.

The camp that prefers to freeze rates at current levels believes rates are high enough to tame inflation and worry that additional rate hikes could tip the economy into recession. Twelve of the Fed’s 19 governors and regional bank presidents health care stocks predicted one more hike, but seven expect rates to stay at the current level. The Fed last week voted to leave interest rates unchanged at a range of 5.25% to 5%, but the bank also signaled it could raise rates once more this year.